Heartflow (NASDAQ:HTFL) Shares Gap Up - Here's Why

Key Points

• Shares of Heartflow, Inc. (NASDAQ:HTFL) gapped up significantly, opening at $32.90, after closing at $31.07, with a last trading price of $33.49.
• Several research firms have initiated coverage on Heartflow, with ratings ranging from "overweight" to "buy" and a consensus target price of $35.80.
• Heartflow has developed an innovative AI-driven platform that has assessed over 400,000 patients for coronary artery disease, underlining its importance in the healthcare sector.

Shares of Heartflow, Inc. (NASDAQ:HTFL - Get Free Report) gapped up before the market opened on Monday . The stock had previously closed at $31.07, but opened at $32.90. Heartflow shares last traded at $33.49, with a volume of 104,688 shares trading hands.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on HTFL. Piper Sandler started coverage on shares of Heartflow in a research note on Tuesday, September 2nd. They issued an "overweight" rating and a $38.00 price objective for the company. JPMorgan Chase & Co. initiated coverage on shares of Heartflow in a report on Tuesday, September 2nd. They issued an "overweight" rating and a $36.00 price target on the stock. Canaccord Genuity Group started coverage on Heartflow in a research report on Tuesday, September 2nd. They set a "buy" rating and a $35.00 target price on the stock. Morgan Stanley assumed coverage on Heartflow in a research report on Tuesday, September 2nd. They set an "equal weight" rating and a $35.00 price objective for the company. Finally, Wall Street Zen upgraded Heartflow to a "hold" rating in a research note on Saturday, August 16th. Four research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat.com, Heartflow has an average rating of "Moderate Buy" and a consensus target price of $35.80.

Heartflow Stock Up 10.6%

About Heartflow

We have pioneered the use of software and AI to deliver a more accurate and clinically effective non-invasive solution for diagnosing and managing coronary artery disease (“CAD”), a leading cause of death worldwide. As of March 31, 2025, our Heartflow Platform has been used to assess CAD in more than 400,000 patients, including 132,000 in 2024 alone.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.